Medicaid Urges States to Tighten Autism Therapy Oversight
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Federal Medicaid officials advised states on Tuesday to impose new restrictions on autism therapy providers to rein in costs that have quintupled since 2021, citing concerns about overprescribing and fraud.
- Medicaid spending on autism therapy hit $10 billion in 2025, up from roughly $2 billion in 2021, while per-child spending more than doubled from a median of $8,903 to $21,203.
- The federal Medicaid office released a 173-page "toolbox" of best practices recommending states set billing limits, require prior authorization for high therapy hours, and better track clinic outcomes.
- Caprice Knapp, a top Medicaid official, told The Times the agency saw "quite an explosion in costs" and wanted to ensure "profit motivation isn't overtaking what's in the best interest of children."
- Current and former clinic workers told The New York Times that profit-oriented clinics were overprescribing therapy hours and even urging some families to pull children from school to qualify for more reimbursable sessions.
- Thousands of new autism clinics have opened in recent years with minimal regulatory oversight, exploiting state mandates that require Medicaid to cover autism treatment.
Why it matters: States that mandate Medicaid autism coverage now face federal pressure to add billing caps, prior authorization, and outcome tracking — a shift that targets the fivefold spending surge but could also restrict access for children who genuinely need intensive therapy. The $10 billion annual price tag, more than doubling per-child spending to $21,203, reveals how rapidly for-profit clinics scaled up under existing rules.
